+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Liver Cancer Diagnostics Market by Test Type, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5716289
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Liver Cancer Diagnostics Market grew from USD 9.41 billion in 2023 to USD 10.05 billion in 2024. It is expected to continue growing at a CAGR of 6.62%, reaching USD 14.74 billion by 2030.

The liver cancer diagnostics market encompasses techniques and tools aimed at identifying liver cancer in its early stages to improve treatment outcomes and survival rates. The necessity for liver cancer diagnostics stems from the increasing prevalence of liver cancer worldwide, driven by factors such as aging populations, rising incidences of hepatitis infections, and increasing alcohol consumption. The application of liver cancer diagnostics encompasses various methods including imaging techniques, biopsy procedures, and biomarker testing, designed to help healthcare providers detect and monitor liver cancer effectively. End-use scope primarily includes hospitals, diagnostic laboratories, and specialty clinics, which rely on these diagnostics for accurate detection and monitoring. Key growth factors influencing this market include technological advancements in imaging and genomic profiling, increased awareness of liver diseases, and the growing demand for early diagnostic methods. As economies develop and healthcare infrastructure improves globally, there is significant market potential in emerging regions. Opportunities lie in advanced molecular diagnostics and artificial intelligence-driven imaging techniques, which promise enhanced accuracy and efficiency. Furthermore, collaborations between technology companies and healthcare providers can accelerate the development of innovative diagnostic tools. However, challenges such as high costs of diagnostic procedures, limited availability in rural areas, and the need for specialized expertise may hinder market growth. Stringent regulatory standards also pose obstacles to the swift commercialization of new technologies. Innovation and research are best focused on affordable, non-invasive testing methods and improving the accessibility of diagnostics in underprivileged areas. The market is competitive, characterized by rapid technological developments and strategic partnerships. For businesses looking to grow, investing in research to develop precision diagnostics and engaging in strategic partnerships with healthcare providers and technology firms can offer a competitive edge. Understanding consumer needs and addressing the gaps in current diagnostic offerings will be vital in shaping the future of liver cancer diagnostics.

Understanding Market Dynamics in the Liver Cancer Diagnostics Market

The Liver Cancer Diagnostics Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing Incidence of liver cancer globally
    • Favorable reimbursement framework for liver cancer diagnosis
    • Growing number of liver cancer screening programs
  • Market Restraints
    • Limited skilled and trained professionals
  • Market Opportunities
    • Technological advancements in cancer diagnosis equipment
    • Focus on development of effective diagnostics
  • Market Challenges
    • Limitations of liver cancer diagnostics

Exploring Porter’s Five Forces for the Liver Cancer Diagnostics Market

Porter’s Five Forces framework further strengthens the insights of the Liver Cancer Diagnostics Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Liver Cancer Diagnostics Market

External macro-environmental factors deeply influence the performance of the Liver Cancer Diagnostics Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Liver Cancer Diagnostics Market

The Liver Cancer Diagnostics Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Liver Cancer Diagnostics Market

The Liver Cancer Diagnostics Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Liver Cancer Diagnostics Market

The Liver Cancer Diagnostics Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Liver Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accuray Incorporated, Biocartis NV, C.R. Bard Inc., Elekta AB, Epigenomics AG, F. Hoffmann-La Roche Ltd., Fujifilm Medical Systems U.S.A., Inc., Illumina, Inc., Koninklijke Philips N.V., Myriad Genetics, Inc., Qiagen N.V., Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Liver Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Test Type
    • Biopsy
    • Endoscopy
    • Imaging
    • Laboratory tests
      • Biomarkers
        • Enzymes & Isoenzymes
        • Growth Factors & Receptors
        • Molecular Markers
        • Oncofetal & Glycoprotein Antigens
        • Pathological Biomarkers
      • Blood Tests
  • End User
    • Academic & Research Institutes
    • Hospitals & Diagnostic Laboratories
    • Pharmaceutical & CRO Laboratories
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing Incidence of liver cancer globally
5.1.1.2. Favorable reimbursement framework for liver cancer diagnosis
5.1.1.3. Growing number of liver cancer screening programs
5.1.2. Restraints
5.1.2.1. Limited skilled and trained professionals
5.1.3. Opportunities
5.1.3.1. Technological advancements in cancer diagnosis equipment
5.1.3.2. Focus on development of effective diagnostics
5.1.4. Challenges
5.1.4.1. Limitations of liver cancer diagnostics
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Liver Cancer Diagnostics Market, by Test Type
6.1. Introduction
6.2. Biopsy
6.3. Endoscopy
6.4. Imaging
6.5. Laboratory tests
6.5.1. Biomarkers
6.5.1.1. Enzymes & Isoenzymes
6.5.1.2. Growth Factors & Receptors
6.5.1.3. Molecular Markers
6.5.1.4. Oncofetal & Glycoprotein Antigens
6.5.1.5. Pathological Biomarkers
6.5.2. Blood Tests
7. Liver Cancer Diagnostics Market, by End User
7.1. Introduction
7.2. Academic & Research Institutes
7.3. Hospitals & Diagnostic Laboratories
7.4. Pharmaceutical & CRO Laboratories
8. Americas Liver Cancer Diagnostics Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Liver Cancer Diagnostics Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Liver Cancer Diagnostics Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. LIVER CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 2. LIVER CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 9. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 11. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 13. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. LIVER CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 19. LIVER CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. LIVER CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. LIVER CANCER DIAGNOSTICS MARKET DYNAMICS
TABLE 7. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ENZYMES & ISOENZYMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROWTH FACTORS & RECEPTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR MARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ONCOFETAL & GLYCOPROTEIN ANTIGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGICAL BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & CRO LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 39. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 40. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 41. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 42. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 43. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 44. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 45. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 57. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 58. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 59. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 61. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 62. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 63. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 65. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 66. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 67. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 69. INDONESIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 70. INDONESIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 71. INDONESIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 73. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 74. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 75. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 77. MALAYSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 78. MALAYSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 79. MALAYSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 81. PHILIPPINES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 82. PHILIPPINES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 83. PHILIPPINES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 85. SINGAPORE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 86. SINGAPORE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 87. SINGAPORE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 89. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 90. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 91. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 93. TAIWAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 94. TAIWAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 95. TAIWAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. THAILAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 97. THAILAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 98. THAILAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 99. THAILAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 101. VIETNAM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 102. VIETNAM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 103. VIETNAM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 109. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 110. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 111. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 112. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 114. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 115. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 116. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 118. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 119. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 120. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 122. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 123. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 124. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 126. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 127. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 128. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 130. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 131. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 132. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 134. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 135. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 136. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 139. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 140. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 142. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 143. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 144. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 146. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 147. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 148. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 150. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 151. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 152. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 154. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 155. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 156. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 170. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 171. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 172. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 178. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 179. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 180. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 182. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 183. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 184. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. LIVER CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 194. LIVER CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Liver Cancer Diagnostics Market, which are profiled in this report, include:
  • Abbott Laboratories
  • Accuray Incorporated
  • Biocartis NV
  • C.R. Bard Inc.
  • Elekta AB
  • Epigenomics AG
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Medical Systems U.S.A., Inc.
  • Illumina, Inc.
  • Koninklijke Philips N.V.
  • Myriad Genetics, Inc.
  • Qiagen N.V.
  • Siemens AG
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.

Methodology

Loading
LOADING...

Table Information